Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a leading player in the medical device industry with a diverse product portfolio that is positioned to drive double-single digit revenue growth. With its broad and innovative product pipeline and potential improvements in operating margins, there is potential for significant growth. The recent strategic investment in MiRus' TAVR system adds to the company's already strong portfolio and could further drive growth and market share gains in the TAVR market.

Bears say

Boston Scientific is facing multiple challenges that could negatively affect its revenue and earnings growth, including previous issues with products in the TAVR market, slower growth in FARAPULSE and WATCHMAN, challenges in Urology and CRM businesses, and lower gross margins and operating margin. While the company has a diversified product portfolio and a strong pipeline, its recent guidance revisions and challenges in various business segments may limit its potential for double-digit growth. Additionally, its recent acquisition and share repurchase plans may not be enough to offset these challenges in the near term.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.